U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801495) titled 'A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis' on Aug. 31.
Brief Summary: The purpose of this Phase 2a/b study is:
1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA).
2. to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.
Study Start Date: Oct. 14
Study Type: INTERVENTIONAL
Condition:
Moderate to Severe Psoriatic Arthritis
Intervention:
DRUG: DDY391
DDY391
DRUG: Placebo
Matching placebo
Recruitment Status: NOT_YET_RECRU...